Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirty-one ratings firms that are covering the firm, ...
Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...
We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at ...
Hosted on MSN11d
Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): ‘This Is Hardly Down For The Year. I Think It Can Still Go Lower’In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the ...
Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) shareholders might be concerned after seeing the share price ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...
Vertex Pharmaceuticals' suzetrigine is an investigational pain treatment. It will seek label expansions thereafter, including ...
Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...
A member of the IBD Big Cap 20, Vertex is a top stock to consider after impressive growth last year. VERX stock could present ...
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback